Mankind Pharma543904Pharmaceuticals
Mankind Pharma's strong Q2 results won brokerage support, with Jefferies and Kotak retaining buy ratings
By ScoutQuest · · 1 min read
- Gross margin
- 72.2 percent
- Chronic therapies portfolio share
- 37.4 percent
- Chronic mix target
- 50 percent
- Kotak projected sales CAGR through FY29
- 20 percent
Heard on business television between 15:46:20 - 15:49:20 IST.
- Improved volumes, margin expansion and domestic pharma growth drove the earnings beat.
- Gross margins improved to 72.2%.
- Chronic therapies contributed 37.4% of the portfolio, with management targeting 50% chronic mix over the next 4-5 years.
- Jefferies and Kotak retained buy ratings, with Kotak building in 20% sales CAGR through FY29.
- Muted consumer healthcare growth remains a key watch point.
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Mankind Pharma
Mankind Pharma investor deck: FY26 revenue crosses ₹14.2k Cr, chronic share targeted at ~50% by FY30, 70% stake in Belgian CAR-T firm ACTx
27 Oct 2026
Mankind Pharma shares jumped 9% after Q2 earnings beat driven by strong domestic pharma growth and margin expansion
27 Oct 2026
Mankind Pharma stock surged nearly 10% after a strong conference call following its results announced during market hours
27 Oct 2026
Source: Live TV News Channel · 27 Oct 2026
The call above is Jefferies, Kotak Institutional Equities's, reported here as they made it. Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.